Qurient Co., Ltd. (KOSDAQ:115180)

South Korea flag South Korea · Delayed Price · Currency is KRW
31,100
-1,500 (-4.60%)
At close: Dec 5, 2025
586.53%
Market Cap 1.21T
Revenue (ttm) 8.28B
Net Income (ttm) -24.13B
Shares Out 39.01M
EPS (ttm) -691.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 280,332
Average Volume 335,730
Open 32,350
Previous Close 32,600
Day's Range 29,650 - 32,350
52-Week Range 3,965 - 33,600
Beta 0.76
RSI 66.68
Earnings Date Mar 17, 2026

About Qurient

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 115180
Full Company Profile

Financial Performance

In 2024, Qurient's revenue was 9.18 billion, an increase of 1.64% compared to the previous year's 9.03 billion. Losses were -23.57 billion, 11.6% more than in 2023.

Financial Statements

News

There is no news available yet.